What Is CRM197 and Why Is It in Vaccines?

CRM197 is a non-toxic form of diphtheria toxin that serves as a carrier protein in some of the most widely used childhood vaccines, including those against pneumococcal disease, meningococcal disease, and Haemophilus influenzae type b (Hib). A single amino acid change strips away the toxin’s dangerous enzymatic activity while preserving the structural features that make it exceptionally useful for training the immune system. Its role in vaccines is less about fighting diphtheria and more about helping the body recognize and remember bacterial sugars it would otherwise ignore, and its story extends well beyond immunization.

How a Single Mutation Disarms Diphtheria Toxin

Diphtheria toxin kills human cells by shutting down their protein-making machinery. It does this through an enzyme that attaches a chemical group onto a critical cellular protein called elongation factor 2, halting protein synthesis. CRM197 differs from the wild-type toxin by just one DNA base change: a G-to-A swap in the gene that results in glutamic acid sitting where glycine normally would at position 52. That substitution knocks out the toxin’s enzymatic activity entirely.

When researchers solved the three-dimensional structure of CRM197 and compared it to wild-type diphtheria toxin, they found the two proteins fold into nearly identical shapes. The critical difference is a flexible loop near the active site that, in CRM197, covers the pocket where the toxin would normally bind its substrate. In the wild-type toxin that loop stays open, ready to accept the substrate and carry out the lethal reaction. In CRM197, the loop flops over the pocket and blocks it.

More recent computational work has shown that the mutation at position 52 also sends ripple effects through the protein, subtly altering the receptor-binding domain at the opposite end of the molecule. These allosteric shifts further destabilize the binding pocket, reinforcing the protein’s inability to act as a toxin.

Why Vaccines Need a Carrier Protein

Many dangerous bacteria wear a coat of sugar chains, called polysaccharides, on their surfaces. In theory, if you could teach the immune system to recognize those sugars, you could prevent infection. The problem is that polysaccharides on their own provoke a weak, short-lived immune response, especially in infants and toddlers. Young children’s immune systems essentially shrug at sugar molecules presented in isolation: they produce some antibodies, but those antibodies fade quickly and the body does not build lasting memory.

Conjugate vaccines solve this by chemically linking the bacterial sugar to a protein the immune system already knows how to handle. The protein acts as a flag that recruits T cells into the response. Those T cells then help B cells make stronger, longer-lasting antibodies against the attached sugar. The protein is not the target of protection; it is the bait that pulls the immune system’s heavy machinery into the fight against the sugar. CRM197 is one of several proteins used for this purpose, and it has become one of the most common.

Vaccines That Rely on CRM197

The best-known CRM197-based vaccines protect against pneumococcal disease. Prevnar 7, the original seven-valent pneumococcal conjugate vaccine, used CRM197 to link seven types of pneumococcal polysaccharide to the carrier protein. Its successor, Prevnar 13, expanded coverage to thirteen serotypes using the same approach, and clinical evaluation confirmed it matched or exceeded the immune responses of the earlier vaccine while maintaining a strong safety profile.⁴ Newer pneumococcal vaccines have pushed valency even higher, with 15-valent and 20-valent products now in use. A systematic review of CRM197-based pneumococcal conjugate vaccines in young children found that antibody levels after a full childhood schedule exceeded the threshold considered protective against invasive pneumococcal disease for all included serotypes, with seroresponse rates above 95% for nearly all of them. Serotype 3 was a consistent outlier, with somewhat lower antibody levels and seroresponse rates in the 84 to 92% range. The review also noted a general trend: as vaccines include more serotypes, antibody concentrations for any individual serotype tend to dip slightly.

⁵

CRM197 also underpins the quadrivalent meningococcal conjugate vaccine Menveo, which covers serogroups A, C, W-135, and Y. Clinical trials found that Menveo produced immune responses at least as strong as those from an older meningococcal conjugate vaccine across adolescents, adults, and even people aged 56 to 65, with immunogenicity also demonstrated in infants and young children.⁶ Its tolerability profile has been described as similar to that of a plain polysaccharide vaccine, which is a favorable comparison since polysaccharide vaccines are generally well tolerated.

⁷

CRM197 played a pivotal role in the development of Hib conjugate vaccines as well. Early clinical trials comparing a CRM197-oligosaccharide Hib conjugate (known as HbOC) to an older polysaccharide-diphtheria toxoid conjugate found that the CRM197 version achieved roughly 95% protection against invasive Hib disease after two doses, with no cases occurring after the booster.⁸ The CRM197-based Hib vaccine was particularly effective at generating strong responses in very young infants, a population that had been difficult to protect with earlier formulations. In early-phase testing, the CRM197 conjugate elicited strong antibody rises including an important IgG component and bactericidal activity even in infants as young as 12 to 16 months, whereas a diphtheria toxoid conjugate did not produce the same level of response in that age group.

⁹

Why CRM197 Has Advantages Over Diphtheria Toxoid

The older approach to making carrier proteins from diphtheria toxin involves treating the toxin with formaldehyde to chemically inactivate it, producing diphtheria toxoid. This process works, and diphtheria toxoid remains in use in some vaccines. But the formaldehyde treatment is blunt: it cross-links amino acids somewhat randomly across the protein’s surface, which can obscure some of the molecular features that T cells need to recognize.

CRM197 avoids this entirely. Because it is already non-toxic due to its genetic mutation, no chemical detoxification is needed. This preserves the protein in a cleaner, more uniform state. Research comparing the two carriers in animal models of meningococcal conjugate vaccination found that prior exposure to CRM197 enhanced both T cell activation and the antibody response directed at the bacterial sugar. Prior exposure to diphtheria toxoid, by contrast, constrained T cell activation, and in some cases led to a phenomenon called carrier-induced epitopic suppression, where high-dose priming with the carrier actually dampened the response to the sugar portion of the conjugate vaccine.¹⁰ The researchers suggested that formaldehyde treatment of diphtheria toxoid may be to blame for the limited antigen presentation to T cells, since stimulating splenocytes from toxoid-primed animals with the unmodified CRM197 protein did not show the same suppression.

An earlier study from the same group had already demonstrated this divergence, showing that CRM197-primed mice developed an enhanced antibody response to the carbohydrate component of the conjugate, while mice primed with diphtheria toxoid or tetanus toxoid were at risk of suppressed responses to the sugar.¹¹ The practical implication is that in populations already immunized against diphtheria (which is most children in countries with routine vaccination schedules), using CRM197 as a conjugate carrier may produce better sugar-directed immunity than using diphtheria toxoid.

How Sugars Are Attached to CRM197

The effectiveness of a conjugate vaccine depends not just on which carrier protein and which sugar you pick, but on how they are linked. Most CRM197-based conjugates attach sugars to the primary amine side chains of lysine residues on the protein’s surface, though in principle the N-terminus, cysteine residues, or carboxyl side chains can also serve as attachment points.¹² CRM197 has 39 lysine residues, but not all of them are equally accessible or equally useful. Research mapping the reactivity of each lysine found that some are far more reactive than others, and that by using two-step conjugation chemistry researchers can attach sugars in a controlled, well-defined manner rather than decorating the protein randomly.

¹³

This matters because where the sugar lands on the protein affects which parts of the carrier remain exposed to T cells. If too many sugars pile onto the protein’s T cell epitopes, those critical stretches get buried and the carrier cannot do its job of recruiting T cell help. A well-designed conjugation strategy preserves the T cell epitopes while maximizing the number of sugar chains displayed on the protein. CRM197’s well-characterized structure, high purity, and the availability of its lysine residues make it especially amenable to this kind of precision conjugation.

¹⁴

Manufacturing CRM197 at Scale

Traditionally, CRM197 was produced by growing the mutant strain of Corynebacterium diphtheriae that naturally carries the altered gene, then purifying the protein from the culture medium. This works, but the organism is slow-growing and yields are modest, which contributes to cost, a serious concern for vaccines intended for global use in low- and middle-income countries.

An alternative is to produce CRM197 as a recombinant protein in Escherichia coli, a workhorse of biotechnology. One optimized process achieved yields above 3 grams per liter by directing the protein to E. coli’s periplasm, a compartment that helps the protein fold correctly. That represents roughly a 20-fold yield improvement over the traditional Corynebacterium-based process.¹⁵ Higher yields per batch mean lower cost per dose, which is directly relevant to expanding vaccine access worldwide.

With multiple manufacturers now producing CRM197 using different expression systems, the question of comparability across suppliers becomes important. An analytical study assessed CRM197 proteins from five different manufacturers and three different expression systems using a battery of structural and antigenic assays, establishing methods to monitor key structural features and ensure that different batches are functionally equivalent.

¹⁶

Engineered Versions for Higher-Valency Vaccines

As pneumococcal vaccines have expanded from 7 to 13 to 15 to 20 serotypes, a practical problem has emerged: every additional sugar conjugated to CRM197 risks crowding out T cell epitopes or overwhelming the carrier’s capacity, potentially weakening the response to individual serotypes. The systematic review of CRM197-based pneumococcal vaccines mentioned earlier confirmed a “downward trend” in antibody levels as valency increases.⁵

One response to this challenge is to engineer the carrier protein itself. A next-generation carrier called eCRM, based on the CRM197 sequence, has been developed using cell-free protein synthesis. This engineered version incorporates non-native amino acids at carefully chosen positions outside the primary T cell epitope regions. Sugars are then attached exclusively at those non-native sites, leaving the T cell epitopes fully exposed. The approach reduces the structural randomness of traditional conjugation, increases the ratio of sugar to protein, and is designed to minimize carrier-mediated immunological interference when many serotypes share a single carrier. Preclinical testing of a 24-valent pneumococcal conjugate vaccine built on this platform has been reported.

¹⁷

CRM197 in Cancer Research

CRM197’s usefulness outside of vaccines stems from a separate property: it binds to heparin-binding epidermal growth factor-like growth factor, commonly called HB-EGF. This growth factor is overexpressed in many types of cancer, where it drives cell proliferation, blood-vessel formation, and invasion into surrounding tissue. CRM197 binds specifically to the EGF-like domain of human HB-EGF and inhibits its ability to stimulate cell growth, without affecting other growth factors that use the same receptor.¹⁸

In studies of oral cancer cells, CRM197 reduced HB-EGF expression, inhibited cell proliferation, and lowered invasiveness. When tested in mice bearing tumor grafts, CRM197 suppressed tumor growth at a dose of 1 mg/kg/day, and combining it with the chemotherapy drug cisplatin at the same dose completely prevented tumor formation.¹⁹ More recent work in lung cancer cells transformed by arsenic exposure found that CRM197 inhibited cell proliferation, arrested the cell cycle, and in live animal models reduced tumor volume and weight more effectively than afatinib, an established targeted cancer drug.²⁰

These are early-stage findings, mostly from cell cultures and mouse models, so they are a long way from becoming treatments you would receive at a clinic. But the fact that CRM197 already has an extensive human safety record from decades of vaccine use makes it an appealing candidate for further clinical development. Its specificity for HB-EGF means it is not a broad-spectrum poison for dividing cells the way traditional chemotherapy drugs are, and it has been proposed as a potential option for cancers that have become resistant to standard therapies.

²¹

Ferrying Drugs Across the Blood-Brain Barrier

The blood-brain barrier is one of medicine’s most frustrating obstacles. It protects the brain by blocking most molecules from crossing out of the bloodstream and into brain tissue, but it also blocks drugs that need to get there to treat conditions like brain tumors, HIV-related neurological damage, and neurodegenerative diseases. CRM197 can cross this barrier because it binds to the diphtheria toxin receptor, which is expressed on the surface of human brain blood-vessel cells. Lab studies using a cell-culture model of the blood-brain barrier showed that CRM197 preferentially crosses from the blood side to the brain side through a process involving small membrane-bound vesicles called caveolae.²²

Researchers have tested whether this property can be harnessed to carry drug payloads into the brain. In one study, CRM197 was grafted onto tiny polymer nanoparticles loaded with zidovudine, an antiviral drug used against HIV. Increasing the amount of CRM197 on the nanoparticle surface increased both the uptake of the particles by brain blood-vessel cells and the permeability of the drug across the barrier model.²³ Proof-of-concept experiments in guinea pigs have also demonstrated brain uptake of a model protein drug conjugated to CRM197.¹⁴ As with the cancer research, this work is still preclinical, but the same advantage applies: CRM197 has a long safety track record in humans, which lowers the bar for moving it into clinical trials as a drug-delivery vehicle. And because researchers already know its receptor-binding domain, conjugation chemistry, and manufacturing process in detail, it comes with fewer unknowns than a novel targeting molecule designed from scratch.